MedTrace Logo

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia

NCT05763550 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2023-11-08

No results posted yet for this study

Summary

Investigate the efficacy and safety of HSK16149 capsules in Chinese herpetic Neuralgia following 4 weeks treatment in comparison to pregabalin.

Conditions

  • Herpetic Neuralgia

Interventions

DRUG

HSK16149 20mg BID

HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.

DRUG

HSK16149 40mg BID

HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.

DRUG

Pregabalin 150mg

pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Fangqiong Li · Haisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2023-06-22
Completion
2023-08-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05763550 on ClinicalTrials.gov